The Journal of antimicrobial chemotherapy
-
J. Antimicrob. Chemother. · Sep 2005
Review Meta AnalysisEvidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
There is still no consensus on the efficacy of antifungal prophylaxis in neutropenic patients after more than 50 clinical trials. ⋯ Itraconazole is recommended for antifungal prophylaxis in high-risk neutropenic patients with haematological malignancies or for prolonged prophylaxis after allogeneic stem cell transplantation based on unambiguous evidence of efficacy and low toxicity from clinical trials and systematic reviews.
-
J. Antimicrob. Chemother. · Sep 2005
ReviewStrategies for managing systemic fungal infection and the place of itraconazole.
Systemic fungal infections are an increasing cause of mortality and morbidity in patients with haematological malignancies and certain other conditions associated with profound immunosuppression. The majority of such infections are caused by Aspergillus and Candida species. In recent years, the number of available drugs effective in the therapy of these difficult infections has expanded. ⋯ In the empirical setting, large randomized studies support the use of caspofungin and liposomal amphotericin B. Voriconazole and lipid-associated amphotericin B have been shown to be effective in first-line therapy and caspofungin for salvage. New approaches to management include efforts at improving diagnosis, combination antifungal therapy and treatment strategies for emerging moulds.